These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

Takeover bid is opportunistic and undervalued: THL
Markets

Takeover bid is opportunistic and undervalued: THL

Tourism Holdings' board remains open to engagement with the Consortium.

One man, five boards: The NZ director spiderweb
Markets

One man, five boards: The NZ director spiderweb

James Miller is at the top of the directorship pyramid.

Increased US tariffs drive NZ stocks lower
Markets Market Close

Increased US tariffs drive NZ stocks lower

F&P Healthcare and Ebos shares both dropped over 2% on the tariff news.

Jamie Gray 01 Aug 2025
Journee to succeed Withers as Warehouse chair
Retail

Journee to succeed Withers as Warehouse chair

Journee ensures "strong continuity of leadership", Joan Withers said.

Gregor Thompson 01 Aug 2025